NCT01516879
Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study
See it on ClinicalTrials.gov ↗905 people
52.4%
47.6%
474 womenmiddle line = equal numbers431 men
- Phase
- PHASE3
- Paid for by
- Amgen
- Finished
- 2013-10-14
- Health conditions
- Hypercholesterolemia
- Who could join
- Anyone
- Ages
- 18 Years – 80 Years
- Average age
- mean 56.1 years
- Age 65+
- Not reported
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- White 80.3% · Black / African American 8.4% · Asian 6.3% · Other 4.3% · American Indian / Alaska Native 0.3% · More than one race 0.2% · Native Hawaiian / Pacific Islander 0.1%
Women left out
- No heart disease
Women with heart disease, heart rhythm problems or a past heart attack were turned away.
“New York Heart Association (NYHA) II-IV heart failure, or last known left ventricular ejection fraction \< 30%”
- No diabetes
Women with diabetes were turned away.
“Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or stroke within 3 months prior to randomization, type 1 diabetes, newly diagnosed or poorly controlled type 2 diabetes”
Study titles and rules are shown in their original English.